Home

EDV
EDV
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal

The completely unique mechanism of action of the world’s first COVID-19 vaccine to stimulate “high affinity” antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023).

You can view the publication here. 

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Click for full story

Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.